@article{2ba84542c96d4a1e9800f73cc1699f66,
title = "Alemtuzumab: Key for Minimization of Maintenance Immunosuppression in Reconstructive Transplantation?",
abstract = "Minimization of immunosuppression has become the key effort in solid organ transplantation. Alemtuzumab, the humanized CD-52 monoclonal antibody, is an effective depleting agent increasingly used in transplantation trials. In this article, we summarize the current experience with alemtuzumab use in hand transplantation and discuss its role in current and future approaches toward minimization of maintenance immunosuppression in reconstructive transplantation.",
author = "S. Schneeberger and L. Landin and C. Kaufmann and Gorantla, {V. S.} and G. Brandacher and P. Cavadas and Lee, {W. P.A.} and Breidenbach, {W. C.} and R. Margreiter",
note = "Funding Information: Supported by TILAK Foundation, Innsbruck, Austria, and by the US Army Medical Research and Marteriel Command under Award No. W81XWH-07-1-0185, and the US Office of Navy Research under Award No. N000140610084. Opinions, interpretations, conclusions and recommendations are those of the authors and not necessarily endorsed by the US Army or the US Navy. ",
year = "2009",
month = mar,
doi = "10.1016/j.transproceed.2009.01.018",
language = "English (US)",
volume = "41",
pages = "499--502",
journal = "Transplantation proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "2",
}